access breakthrough technology to better detect ovarian cancer RISK
with Aspira Women's Health
The Challenge of Reliable Ovarian Cancer Screening
For the past few decades, there has been limited progress in the development of reliable ovarian cancer screening methods. During this time, the CA125 blood test has been one of the primary tools used to assess the risk of ovarian cancer. Unfortunately, the CA125 test has significant limitations, as it measures a protein that can be elevated in ovarian cancer but also in several benign conditions like endometriosis and pelvic inflammatory disease. More importantly, not all ovarian cancers produce elevated CA125 levels, especially in early stages. This has resulted in a high rate of false positives and false negatives, making the CA125 test an unreliable tool for accurate early detection and risk assessment.
THE BREAKTHROUGH by Aspira Women's Health
Aspira Women's Health has introduced a breakthrough in ovarian cancer risk assessment with the OvaWatch® and Ova1Plus® tests, part of the OvaSuiteSM product suite. These tests performed in CLIA certified Laboratory represent a monumental step forward in early ovarian cancer risk detection and management, offering physicians a more reliable means to assess adnexal masses—a common but concerning condition that affects over 1.2 million women in the U.S. and approximately 140,000 in Canada each year.
Unlike traditional single biomarker tests like CA125, Ova1®
and OvaWatch® blood tests use a combination of several
biomarkers along with patient-specific factors such as menopausal
status. These tests offer much-needed advancement, helping guide
clinical decisions with greater confidence and reducing the
uncertainty often associated with the diagnosis of an adnexal mass.
About ASPIRA WOMEN's HEALTH
Aspira Women's Health is dedicated to the discovery, development and utilization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Using decades of experience in ovarian cancer risk assessment, Aspira is developing a cutting-edge portfolio of pelvic mass products.
what is ovawatch® and ova1plus®?
OvaWatch® is an incredibly accurate test with a 99% rate in determining whether an adnexal mass is benign. This allows doctors to make more informed decisions about whether immediate surgery is necessary or if the patient can be safely monitored. Meanwhile, Ova1Plus® is used when surgery is already planned, by combining the two tests (Ova1® and Overa®) to evaluate the likelihood of cancer before the procedure. These tests are not only crucial in improving the accuracy of diagnosis but also in ensuring that patients receive the right care from specialists in gynecological oncology when surgery is required.
Note: Ova1® is a test performed in a CLIA-certified lab. Unlike OvaWatch®, Ova1® has received FDA clearance as a risk assessment tool for evaluating the likelihood of ovarian cancer in women with a pelvic mass planned for surgery."
A typical clinical management of suspicious ovarian cancer patient
HOW IS THE TEST ADMINISTERED?
In the United States, the OvaWatch® and Ova1Plus® tests are simple and straightforward, requiring only a single blood draw, which can be done at various national and regional laboratories or in a healthcare provider’s office using a proprietary testing kit.
For women in Canada, while this convenient option is not yet available, the test can still be ordered through your physician. A blood sample will be collected and sent to an Aspira Lab for analysis. The Joan Rotondi Hope & Empowerment Foundation is actively working to make this test more accessible in Canada. Our goal is to enable women to visit a local lab for a blood draw that will test for seven specific bio markers. The results will then be sent to Aspira in the U.S., where they will be processed through their advanced algorithm to produce a detailed report, which will be sent directly to your physician.
JRHEF is committed to making this vital test as accessible as possible to all women experiencing symptoms and concerned about ovarian cancer.
Comparison of OvaWatch® & OVA1® with Traditional Ovarian
Cancer Detection Tests
¹ Sensitivity focuses on how well the test identifies actual cases of the disease (avoiding false negatives among those who are sick)
² A biomarker in a blood test is a measurable substance in your blood that can indicate a normal or abnormal condition in your body, such as a disease or infection.
encouraging public and professional accessibility
For women who are concerned about their symptoms and are interested in learning more about how to order a test kit, we invite you to click the Get Started button below. Our foundation is here to support you every step of the way, from understanding your options to accessing the care you need.
JRHEF strongly encourages medical professionals to contact Aspira Women's Health directly to learn more about these revolutionary tests and their critical role in early ovarian cancer risk detection.
Privacy & Security: We understand the importance of privacy when disclosing personal health data. It’s crucial to know that any information provided for OvaWatch® or Ova1Plus® test kits is not viewed or collected by JRHEF. Your data is securely stored and managed exclusively by Aspira Women's Health, ensuring that your personal and medical information remains confidential and protected.
Our Mission and Your Support
JRHEF is committed to spearheading awareness campaigns across Canada to ensure that women and healthcare providers are informed about these life-saving tools. The vast majority of physicians are still unaware of the existence and significance of these tests. By partnering with Aspira Women's Health, we aim to bridge this knowledge gap, helping medical professionals better understand the importance of these tests in ovarian cancer detection and management. Your generous donations will help us enhance accessibility to test kits and support women in need, ensuring they receive these crucial diagnostic tools.
Donations can be made via our Donate button—thank you for helping us make a difference.